title: Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.
abstract: BACKGROUND
  Accumulating evidence suggests that risk factors for classical Hodgkin lymphoma (cHL) differ by tumor Epstein-Barr virus (EBV) status. This potential etiological heterogeneity is not recognized in current disease classification.
  
  
  METHODS
  We conducted a genome-wide association study of 1200 cHL patients and 6417 control subjects, with validation in an independent replication series, to identify common genetic variants associated with total cHL and subtypes defined by tumor EBV status. Multiple logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) assuming a log-additive genetic model for the variants. All statistical tests were two-sided.
  
  
  RESULTS
  Two novel loci associated with total cHL irrespective of EBV status were identified in the major histocompatibility complex region; one resides adjacent to MICB (rs2248462: OR = 0.61, 95% CI = 0.53 to 0.69, P = 1.3 × 10(-13)) and the other at HLA-DRA (rs2395185: OR = 0.56, 95% CI = 0.50 to 0.62, P = 8.3 × 10(-25)) with both results confirmed in an independent replication series. Consistent with previous reports, associations were found between EBV-positive cHL and genetic variants within the class I region (rs2734986, HLA-A: OR = 2.45, 95% CI = 2.00 to 3.00, P = 1.2 × 10(-15); rs6904029, HCG9: OR = 0.46, 95% CI = 0.36 to 0.59, P = 5.5 × 10(-10)) and between EBV-negative cHL and rs6903608 within the class II region (rs6903608, HLA-DRA: OR = 2.08, 95% CI = 1.84 to 2.35, P = 6.1 × 10(-31)). The association between rs6903608 and EBV-negative cHL was confined to the nodular sclerosis histological subtype. Evidence for an association between EBV-negative cHL and rs20541 (5q31, IL13: OR = 1.53, 95% CI = 1.32 to 1.76, P = 5.4 x 10(-9)), a variant previously linked to psoriasis and asthma, was observed; however, the evidence for replication was less clear. Notably, one additional psoriasis-associated variant, rs27524 (5q15, ERAP1), showed evidence of an association with cHL in the genome-wide association study (OR = 1.21, 95% CI = 1.10 to 1.33, P = 1.5 × 10(-4)) and replication series (P = .03).
  
  
  CONCLUSIONS
  Overall, these results provide strong evidence that EBV status is an etiologically important classification of cHL and also suggest that some components of the pathological process are common to both EBV-positive and EBV-negative patients.
authors.affiliation: Genetics Section, International Agency for Research on Cancer, Lyon, France.
authors.forename: Kevin Y
authors.initials: KY
authors.lastname: Urayama
authors.forename: Ruth F
authors.initials: RF
authors.lastname: Jarrett
authors.forename: Henrik
authors.initials: H
authors.lastname: Hjalgrim
authors.forename: Arjan
authors.initials: A
authors.lastname: Diepstra
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Kamatani
authors.forename: Amelie
authors.initials: A
authors.lastname: Chabrier
authors.forename: Valerie
authors.initials: V
authors.lastname: Gaborieau
authors.forename: Anne
authors.initials: A
authors.lastname: Boland
authors.forename: Alexandra
authors.initials: A
authors.lastname: Nieters
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Becker
authors.forename: Lenka
authors.initials: L
authors.lastname: Foretova
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Benavente
authors.forename: Marc
authors.initials: M
authors.lastname: Maynadié
authors.forename: Anthony
authors.initials: A
authors.lastname: Staines
authors.forename: Lesley
authors.initials: L
authors.lastname: Shield
authors.forename: Annette
authors.initials: A
authors.lastname: Lake
authors.forename: Dorothy
authors.initials: D
authors.lastname: Montgomery
authors.forename: Malcolm
authors.initials: M
authors.lastname: Taylor
authors.forename: Karin Ekström
authors.initials: KE
authors.lastname: Smedby
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Amini
authors.forename: Hans-Olov
authors.initials: HO
authors.lastname: Adami
authors.forename: Bengt
authors.initials: B
authors.lastname: Glimelius
authors.forename: Bjarke
authors.initials: B
authors.lastname: Feenstra
authors.forename: Ilja M
authors.initials: IM
authors.lastname: Nolte
authors.forename: Lydia
authors.initials: L
authors.lastname: Visser
authors.forename: Gustaaf W
authors.initials: GW
authors.lastname: van Imhoff
authors.forename: Tracy
authors.initials: T
authors.lastname: Lightfoot
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Cocco
authors.forename: Lambertus
authors.initials: L
authors.lastname: Kiemeney
authors.forename: Sita H
authors.initials: SH
authors.lastname: Vermeulen
authors.forename: Ivana
authors.initials: I
authors.lastname: Holcatova
authors.forename: Lars
authors.initials: L
authors.lastname: Vatten
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Macfarlane
authors.forename: Peter
authors.initials: P
authors.lastname: Thomson
authors.forename: David I
authors.initials: DI
authors.lastname: Conway
authors.forename: Simone
authors.initials: S
authors.lastname: Benhamou
authors.forename: Antonio
authors.initials: A
authors.lastname: Agudo
authors.forename: Claire M
authors.initials: CM
authors.lastname: Healy
authors.forename: Kim
authors.initials: K
authors.lastname: Overvad
authors.forename: Anne
authors.initials: A
authors.lastname: Tjønneland
authors.forename: Beatrice
authors.initials: B
authors.lastname: Melin
authors.forename: Federico
authors.initials: F
authors.lastname: Canzian
authors.forename: Kay-Tee
authors.initials: KT
authors.lastname: Khaw
authors.forename: Ruth C
authors.initials: RC
authors.lastname: Travis
authors.forename: Petra H M
authors.initials: PH
authors.lastname: Peeters
authors.forename: Carlos A
authors.initials: CA
authors.lastname: González
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Quirós
authors.forename: María-José
authors.initials: MJ
authors.lastname: Sánchez
authors.forename: José María
authors.initials: JM
authors.lastname: Huerta
authors.forename: Eva
authors.initials: E
authors.lastname: Ardanaz
authors.forename: Miren
authors.initials: M
authors.lastname: Dorronsoro
authors.forename: Françoise
authors.initials: F
authors.lastname: Clavel-Chapelon
authors.forename: H Bas
authors.initials: HB
authors.lastname: Bueno-de-Mesquita
authors.forename: Elio
authors.initials: E
authors.lastname: Riboli
authors.forename: Eve
authors.initials: E
authors.lastname: Roman
authors.forename: Paolo
authors.initials: P
authors.lastname: Boffetta
authors.forename: Silvia
authors.initials: S
authors.lastname: de Sanjosé
authors.forename: Diana
authors.initials: D
authors.lastname: Zelenika
authors.forename: Mads
authors.initials: M
authors.lastname: Melbye
authors.forename: Anke
authors.initials: A
authors.lastname: van den Berg
authors.forename: Mark
authors.initials: M
authors.lastname: Lathrop
authors.forename: Paul
authors.initials: P
authors.lastname: Brennan
authors.forename: James D
authors.initials: JD
authors.lastname: McKay
mesh_terms: D000626:Aminopeptidases / Q000378:metabolism; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D055106:Genome-Wide Association Study; D059805:HLA-DR alpha-Chains / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006689:Hodgkin Disease / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000821:virology; D006801:Humans; D016015:Logistic Models; D015778:Minor Histocompatibility Antigens; D016017:Odds Ratio; D012307:Risk Factors
chemical_list: D059805:HLA-DR alpha-Chains; D015395:Histocompatibility Antigens Class I; C098080:MICB antigen; D015778:Minor Histocompatibility Antigens; D000626:Aminopeptidases; C464841:ERAP1 protein, human